The aim of the present prospective study is to investigate the predictive role of quantitative, dynamic 18F-FDG PET/CT performed early during immunotherapy in metastatic melanoma patients undergoing treatment with PD-1 inhibitors. This evidence concerns the gene PDCD1 and metastatic melanoma.